Early Α-Fetoprotein Response Predicts Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Journal of Hepatocellular Carcinoma
doi 10.2147/jhc.s79353
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Post-Progression Survival and Progression-Free Survival in Patients With Advanced Hepatocellular Carcinoma Treated by Sorafenib

Hepatology Research
HepatologyInfectious Diseases
2015English

Attenuation of Liver Stiffness in Sorafenib-Treated Patients With Advanced Hepatocellular Carcinoma

Hepatoma Research
2017English

Long Duration of Stable Disease May Improve Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Acta Hepatologica Japonica
Hepatology
2012English

Neutrophil-To-Lymphocyte Ratio Predicts Survival in European Patients With Hepatocellular Carcinoma Administered Sorafenib

Oncotarget
Oncology
2017English

Advanced Hepatocellular Carcinoma: Pretreatment Contrast-Enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated With Sorafenib

Radiology
Nuclear MedicineRadiologyImaging
2018English

Sorafenib Combined With Hepatectomy in Patients With Intermediate-Stage and Advanced Hepatocellular Carcinoma

Archives of Medical Science
Medicine
2017English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

The Three Criteria for Radiological Response on Survival in Patients With Hepatocellular Carcinoma Treated With Lenvatinib

Hepatology Research
HepatologyInfectious Diseases
2019English

Level of Α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C–Related Hepatocellular Carcinoma

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy